Lions waive edge rusher James Houston: ‘It just never quite worked out’
CALHOUN COUNTY, Ga. and FORT WAYNE, Ind. , Dec. 6, 2024 /PRNewswire/ -- Calhoun County E911 has achieved a significant milestone in November as the first in the United States to implement Ryzyliant's revolutionary EDGETM platform, seamlessly integrated with INdigital's Next Generation Core Services (NGCS). This partnership marks a leap forward in delivering agile, reliable, and community-focused emergency response capabilities. This deployment is a groundbreaking achievement for Calhoun County , one of Georgia's smaller Public Safety Answering Points (PSAPs) with two positions. It is also INdigital's third live NGCS customer in Georgia , underscoring the company's growing presence and commitment to advancing public safety infrastructure across the state. As the NGCS provider for Calhoun County , INdigital ensured the seamless delivery of 911 calls and integrated Ryzyliant's EDGETM platform into the Emergency Services IP Network (ESInet). This integration, combined with Ryzyliant's hybrid cloud-hosted solution with local survivability, provides unmatched resilience, efficiency, and security. Ryzyliant's EDGETM platform simplifies emergency call handling with integrated features such as NG9-1-1 call taking, mapping, and computer-aided dispatch (CAD). Powered by INdigital's reliable NGCS circuits, the system ensures rapid response times and full compliance with evolving NG9-1-1 standards. "This partnership represents the future of public safety technology," said Eric Hartman , Vice President of INdigital. "By combining INdigital's robust NGCS infrastructure with Ryzyliant's cutting-edge EDGE platform, we're ensuring that every 911 call is delivered and answered with precision, no matter the circumstances." INdigital's local backup capabilities and proven expertise in NGCS projects were instrumental in this deployment. The company also provided database services and implemented Texty, enabling text-to-911 functionality for the county. These services ensure that Calhoun County E911 is prepared to respond to the community's needs with the most reliable tools available. "Delivering 9-1-1 calls is INdigital's mission, and with Ryzyliant's innovative platform, Calhoun County now has the tools to handle and respond to calls seamlessly," said Caleb Branch , Vice President of Market Management at INdigital. "This collaboration exemplifies our shared commitment to enhancing public safety operations nationwide." The successful implementation in Calhoun County highlights the synergy between INdigital and Ryzyliant, setting a new standard for NG9-1-1 solutions. As public safety agencies across the country transition to next-generation systems, this collaboration demonstrates how advanced technology and reliable infrastructure can work hand in hand to serve communities effectively. About INdigital INdigital specializes in delivering Next Generation 9-1-1 services, focusing on agile, reliable, and resilient core services tailored to individual PSAP needs. With a mission to ensure every 9-1-1 call is delivered, INdigital partners with agencies nationwide to support their unique public safety requirements. View original content to download multimedia: https://www.prnewswire.com/news-releases/calhoun-county-e911-becomes-first-to-launch-ryzyliants-solution-with-indigital-ngcs-support-302325294.html SOURCE INdigital
Attorneys want the US Supreme Court to say Mississippi’s felony voting ban is cruel and unusualPITTSBURGH – Pitt’s sophomore linebacker Kyle Louis and junior all-purpose back Desmond Reid have been named to a pair of All-America teams by prestigious national media outlets. Louis and Reid were selected as second-team All-Americans by The Athletic as well as CBS Sports. Each outlet revealed its respective All-America squads Wednesday. It marked the first national postseason honors of Louis’ collegiate career. The 6-foot, 225-pounder established himself as one of college football’s rising stars with a breakthrough sophomore campaign. For Reid, it was the second consecutive year he earned national postseason recognition. He also garnered All-America accolades while starring at Western Carolina in 2023. No defender in the country filled a stat line like Louis this past season. He compiled 96 tackles, 15.5 stops for loss, seven sacks, four interceptions (not including his interception of a two-point conversion pass) and a forced fumble. Reid truly was a do-it-all threat with the ball in his hands this season. He averaged 150.9 all-purpose yards per game to rank sixth nationally. Reid additionally averaged an ACC-best 12.3 yards per punt return, which ranked ninth in the country. Reid is the only player in the nation this season to compile three games with at least 100 receiving yards and 50 rushing yards. That feat was previously accomplished by Stanford's Christian McCaffrey in 2015. Louis and Reid will lead Pitt into its final contest of the season, the GameAbove Sports Bowl against Toledo Dec. 26. The game, held inside Detroit’s Ford Field, will be nationally televised by ESPN and kick off at 2 p.m. (c)2024 The Tribune-Democrat (Johnstown, Pa.) Visit The Tribune-Democrat (Johnstown, Pa.) at www.tribune-democrat.com Distributed by Tribune Content Agency, LLC.OSAKA, Japan & CAMBRIDGE, Mass. — Takeda will host an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products,” said Christophe Weber, Takeda chief executive officer. “The first three Phase 3 programs will read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years.” The late-stage pipeline includes oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), mezagitamab (TAK-079), fazirsiran (TAK-999) and elritercept (TAK-226). Combined these programs have potential peak revenue of $10B – $20B. Data from three Phase 3 programs is expected to read out in 2025: Filings for these three indications are expected in fiscal years 2025 and 2026. Five additional indication filings for late-stage programs are on pace for fiscal years 2027 through 2029: “Takeda has established an exciting, late-stage pipeline of transformative therapies that we believe will deliver value to our company and, most importantly, to the patients we serve around the world,” said Andy Plump, president of R&D at Takeda. “As we continue scaling our capabilities and maximizing R&D investment to deliver the late-stage pipeline, we are also progressing an exciting early-stage pipeline, supporting a cutting-edge research organization, and focusing on creative business development across our therapeutic areas to sustain Takeda’s future and continue to meet significant unmet patient needs.” The meeting includes the following presentations and speakers: Christophe Weber, President & CEO Andy Plump, President, Research and Development Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit and Head of Global Development Ramona Sequeira, President of Global Portfolio Division Chinwe Ukomadu, Head of Gastrointestinal and Inflammation Therapeutic Area Unit Ramona Sequeira, President of Global Portfolio Division Teresa Bitetti, President Global Oncology Business Unit P.K. Morrow, Head of Oncology Therapeutic Area Unit A live webcast of the meeting begins at 8:30 a.m. JST December 13 (6:30 p.m. EST December 12). Presentations are available on the where a video replay will be available following the meeting. Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit . For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: or at . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. References in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda’s Portfolio Review Committee for use in internal planning. This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Elritercept is included for reference only. Takeda entered into an exclusive license agreement with Keros for global rights, in all territories outside of mainland China, Hong Kong and Macau, to Elritercept. The closing of the transaction is subject to receipt of regulatory approval(s), expected in the first calendar quarter of 2025. Takeda does not currently have rights to Elritercept. ___________________________ References in this presentation to peak revenue potential are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. +81 (0) 90-6481-3412
In the upcoming group stage of a major eSports tournament, fans and players alike were shocked to see two powerhouse teams, Invictus Gaming (iG) and Top Esports (TES), drawn into the same group. This unexpected turn of events has set the stage for a highly anticipated reunion of old teammates and intense rivalries between these two top-tier teams.Moreover, tax incentives for home buyers also help to alleviate the financial burden on potential buyers, particularly first-time buyers and those from lower income brackets. By reducing the amount of tax payable on property purchases, these incentives make homeownership more accessible and affordable for a wider range of people. This not only benefits individuals and families looking to own their own homes but also supports the growth of the middle class and stimulates consumption in related industries such as home improvement and furnishing.
UBS's Lefkowitz says U.S. stock valuations are 'reasonable'Furthermore, the social aspect of the "ba ji" phenomenon cannot be overlooked. In today's hyper-connected world, social media plays a significant role in shaping trends, creating communities, and fostering a sense of belonging. The viral nature of the news surrounding the inflated price of the toasted bread may have sparked a sense of curiosity and intrigue among people, driving them to participate in the trend and contribute to its escalating value.
NoneOne defensive lineman ends an 11-year family streak at OSU. Another considers culinary schoolEaton Corp. PLC stock rises Tuesday, still underperforms marketNone
Counterfeiting is a serious crime with far-reaching consequences. Not only does it undermine the integrity of the financial system, but it also poses a threat to businesses and consumers who may unwittingly accept fake currency. The impact of counterfeit money can be devastating, leading to financial losses and eroding trust in the economy.Trump vows to pursue executions after Biden commutes most of federal death row
The sight of suitcases piled high in the lobby is a testament to the popularity of these bathhouses among travelers seeking a unique and indulgent experience. Many visitors come from far and wide to partake in the special treatments and services offered, from invigorating hot stone massages to herbal steam baths and aromatic oil treatments. The allure of these luxurious amenities and the promise of a truly relaxing escape draw in a steady stream of guests, leading to the overflow of suitcases in the lobby.In conclusion, tiptoeing is a whole-body workout that is loved by all organs for its ability to strengthen muscles, improve balance, and boost cardiovascular fitness. By making tiptoeing a regular part of your routine, you can experience a wide range of physical benefits that contribute to your overall health and well-being. So, the next time you find yourself standing in line or waiting for an elevator, take a moment to rise up onto your tiptoes and engage in this simple yet effective exercise that can help you stay fit and healthy anytime, anywhere.
For those unfamiliar with the eSports scene, iG and TES are two of the most successful and well-known teams in the world of competitive gaming, particularly in the MOBA genre. Both teams have achieved great success in international tournaments and have amassed a large following of fans from around the globe.
The implications of the security breach at the Defense Security Command are far-reaching and have raised concerns both domestically and internationally. South Korea is a key player in the region, with a significant military presence and strategic importance in the Asia-Pacific region. Any compromise of its defense capabilities or classified information could have serious implications for regional stability and security.
Jinhui Shipping: Third Quarter and Nine Months Report 2024As World War II entered its final year in 1945, a 19-year-old Army soldier from Columbia got caught an intense battle thousands of miles away from home. Arthur W. Crossland Jr. was fighting German forces in a heavily wooded area near Althorn, France, when a mine exploded, killing him instantly. Facing mortars and machine gun fire, his fellow soldiers had to withdraw from the area before body could be recovered. Crossland died in March 1945 and within six moths the war would be over. The following year, the military began searching for Crossland's remains. Nearly 80 years later, that search has come to an end. Crossland's remains were identified using DNA technology, and now his family can lay him to rest in his hometown. According to a news release from Defense POW/MIA Accounting Agency (DPAA), Crossland will be buried in Columbia on March 14. His remains were recovered from Normandy American Cemetery in Colleville-sur-Mer, France. More than 9,000 U.S. troops are buried at the cemetery, and hundreds of the graves contain unidentified remains. In July 2022, workers from the Department of Defense and American Battle Monuments Commission exhumed the remains of X-535 and transferred them to a laboratory for analysis. Scientists used anthropological and other circumstantial evidence to identify the remains, according to the release. "Additionally, scientists from the Armed Forces Medical Examiner System used mitochondrial DNA (mtDNA) and Y-chromosome DNA (Y-STR) analysis." On Aug. 21, 2024, scientists concluded that the remains of X-535 belonged to Crossland, a private 1st Class soldier assigned to Company L, 3rd Battalion, 242nd Infantry Regiment, 42nd Infantry Division in the European Theater. More than 400,000 U.S. soldiers died in World War II. According to the New York Times, more than 72,000 of them are still unaccounted for. Before Crossland's remains were identified, he had already been memorialized Walls of the Missing at Epinal American Cemetery in Dinozé, France. Now that he has been accounted for, a rose will be placed next to his name.
